Our third example, the ATTRibute-CM trial,29 randomized 632 patients with transthyretin amyloid cardiomyopathy in a 2:1 ratio to acoramidis hydrochloride or placebo. The gene discussed is TTR; the disease is cardiac amyloidosis.